Viral Vector CDMOs — Ranked by Signal Score · 2026

Q: Which viral vector platform does my program need?

The three GMP platforms map to distinct program types. AAV is the dominant delivery platform for in vivo gene therapy — rare disease, ophthalmology, neurology, cardiac, and musculoskeletal indications. It's non-integrating, made at 200-2,000L batch scale in suspension or adherent culture, and every approved in vivo gene therapy uses AAV. Lentivirus is the workhorse for ex vivo cell engineering — CAR-T, TCR, and gene-modified HSC programs use lentivirus to stably integrate the therapeutic gene into patient-bound cells. Lentiviral manufacturing runs at BSL-2 with mandatory replication-competent lentivirus (RCL) testing. Adenovirus retains relevance for vaccines and select gene therapy programs where high transient expression is acceptable — its non-integrating nature and strong immunogenicity make it well-suited for prime-boost vaccine architectures. Most CDMOs specialize in one or two platforms — filter by platform on the AAV, lentiviral, or adenoviral pages for the platform-specific shortlist.

Last updated: 2026-10-22 · updated as new inspection, certificate, and trial data enters the platform

Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

196

EMA/MHRA GMP certs

Warning letters

On CDMO Signal's composite Signal Score, Takeda, Thermo Fisher Scientific, and AGC Biologics lead the viral vector CDMO rankings — an aggregation across AAV, lentiviral, and adenoviral vector manufacturers. The Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. Vector platform is the first cut in any viral vector CDMO shortlist: AAV programs weight suspension platform maturity, serotype experience, and full/empty capsid analytics; lentiviral programs weight BSL-2 containment integrity, RCL testing, and titer + potency assay maturity; adenoviral programs weight yield, process comparability, and thermal stability. See the dedicated AAV, lentiviral, and adenoviral pages for platform-filtered rankings. Full methodology at cdmosignal.com/methodology.

Viral vector CDMOs manufacture the three GMP-relevant vector platforms used in modern gene therapy and gene-modified cell therapy: adeno-associated virus (AAV), lentivirus, and adenovirus. Each platform has distinct process, containment, and analytics requirements, and CDMOs typically specialize in one or two platforms rather than all three. Platform is the first shortlist filter in any viral vector procurement decision.

This ranking aggregates every CDMO tracked as a viral vector manufacturer across the three platforms. For platform-specific rankings with process-critical detail (BSL-2 containment for lentivirus, full/empty capsid analytics for AAV, high-titre transient expression for adenovirus), use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors integrating vector supply with downstream cell processing (CAR-T, gene-modified HSC), the <a href="/modality/cell-and-gene-therapy">cell & gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 20 NAI (no action), 31 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (50), United States (47), Denmark (35), Germany (22), Italy (15).

Last updated 2026-10-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	TK Takeda Boston, MA · Zurich, CH	81.9	99.6	4 insp · 18 GMP	—	100 programs
2	TF Thermo Fisher Scientific Plainville, MA · Alachua, FL · Cambridge, MA	81.0	100.0	6 insp · 10 GMP	Available	2 programs
3	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	78.6	100.0	2 insp · 23 GMP	Available	2 programs
4	OX Oxford Biomedica Oxford, United Kingdom	76.2	100.0	0 insp · 13 GMP	Available	7 programs
5	Lonza Basel, Switzerland	76.0	95.7	2 insp · 8 GMP	—	1 programs
6	CI Cincinnati Children's Vector Production Facility Cincinnati, OH	75.2	100.0	1 insp · 0 GMP	—	1 programs
7	NR National Resilience San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA	74.5	98.0	1 insp · 0 GMP	Available	9 programs
8	RT ReiThera Rome, IT	71.1	100.0	0 insp · 4 GMP	—	1 programs
9	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	90.9	98.3	8 insp · 11 GMP	Limited	0 programs
10	RP ReciBioPharm Keele, UK · Sodertalje, SE	88.0	100.0	0 insp · 3 GMP	—	0 programs
11	PB Pharmaron Biologics San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China	86.9	100.0	3 insp · 0 GMP	Available	0 programs
12	FD FUJIFILM Diosynth Biotechnologies Research Triangle, NC · Holly Springs, NC · Hillerod, DK	84.8	100.0	0 insp · 23 GMP	Expanding	0 programs
13	KB KBI Biopharma Durham, NC · Boulder, CO	84.4	99.1	1 insp · 1 GMP	Limited	0 programs
14	AJ Ajinomoto Bio-Pharma Services San Diego, CA · Osaka, JP	83.5	100.0	0 insp · 1 GMP	—	0 programs
15	WB2 WuXi Biologics Shanghai, CN · Wuxi, CN	82.9	100.0	0 insp · 4 GMP	—	0 programs
16	LB Lotte Biologics Incheon, KR · Syracuse, NY	81.6	100.0	1 insp · 0 GMP	—	0 programs
17	DH Danaher (CGT Portfolio) Washington, DC	81.5	—	—	—	0 programs
18	NW Northway Biotech Vilnius, LT; Waltham (MA), USA	80.8	100.0	0 insp · 8 GMP	Available	0 programs
19	BR BioReliance (Merck) Glasgow, UK · Rockville, MD	80.2	97.1	4 insp · 8 GMP	—	0 programs
20	OB OmniaBio Hamilton, ON	79.5	100.0	0 insp · 2 GMP	—	0 programs
21	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.	79.5	100.0	—	Available	0 programs
22	UM MassBiologics Boston, MA	79.0	97.2	1 insp · 0 GMP	—	0 programs
23	BB bluebird bio Manufacturing Durham, NC	78.5	—	—	—	0 programs
24	AA Ascend Advanced Therapies London, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
25	NG NecstGen Leiden, NL	78.1	100.0	0 insp · 1 GMP	—	0 programs
26	ET Exothera Jumet, BE	78.1	100.0	0 insp · 4 GMP	—	0 programs
27	PG ProBioGen Berlin, DE	78.1	100.0	0 insp · 4 GMP	—	0 programs
28	CE Celonic Basel, Switzerland	78.1	100.0	0 insp · 1 GMP	—	0 programs
29	XP eXmoor Pharma Bristol, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
30	AD Advent Bioservices London, United Kingdom	78.1	100.0	0 insp · 2 GMP	—	0 programs
31	BV Biovian Turku, Finland	78.0	99.8	1 insp · 4 GMP	—	0 programs
32	AG2 August Bioservices San Carlos, CA	77.5	98.7	1 insp · 0 GMP	—	0 programs
33	VG Viralgen Vector Core San Sebastián, Spain	76.8	100.0	0 insp · 4 GMP	Available	0 programs
34	CG Cytiva (Mfg Services) Marlborough, MA · Uppsala, SE	74.0	—	—	—	0 programs
35	Catalent Bagsværd, Denmark (operating under Novo Holdings)	73.1	74.9	12 insp · 37 GMP	—	0 programs
36	CA Catalent (Novo Holdings) Harmans, MD · Gosselies, BE	73.1	74.9	1 insp · 0 GMP	Available	0 programs
37	LZ Lonza Biologics Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH	73.0	95.7	1 insp · 0 GMP	Limited	0 programs
38	VE Vigene Biosciences Rockville, MD	72.5	—	—	—	0 programs
39	GZ Genezen Indianapolis, IN · Lexington, MA	71.5	85.8	3 insp · 0 GMP	Available	0 programs
40	EM Emergent BioSolutions (CGT) Baltimore, MD	71.0	—	—	—	4 programs
41	IU Indiana University Vector Production Facility Indianapolis, IN	66.3	—	—	—	49 programs
42	AN Andelyn Biosciences Columbus, OH	63.0	—	—	Available	0 programs
43	RA Recipharm Advanced Bio Stockholm, Sweden	63.0	—	—	—	0 programs
44	AB Asklepios BioPharmaceutical (AskBio) Research Triangle, NC · San Sebastian, ES	61.8	—	—	—	10 programs
45	GF GeneFab Alameda, CA and South San Francisco	61.5	—	—	Available	0 programs
46	FB Forge Biologics Columbus, OH	61.2	—	—	Expanding	3 programs
47	MA Matica Biotechnology College Station, TX	59.0	—	—	Available	0 programs
48	VB VintaBio Cambridge, MA	59.0	—	—	—	0 programs
49	MS Made Scientific Princeton, NJ	59.0	—	—	—	0 programs
50	WB Waisman Biomanufacturing Madison, WI	59.0	—	—	—	0 programs
51	EB ElevateBio BaseCamp Waltham, MA	59.0	—	—	—	0 programs
52	CP Cell and Gene Therapy Catapult Stevenage, United Kingdom	59.0	—	—	—	0 programs
53	VM Vector BioMed Cambridge, MA	59.0	—	—	—	0 programs
54	AM Anemocyte Gerenzano, Italy	59.0	—	—	—	0 programs
55	HX Helixmith Seoul, KR	59.0	—	—	—	0 programs
56	Vantage Vector (Demo) Gaithersburg, MD	59.0	—	—	Available	0 programs
57	TR Takara Bio Kusatsu, Shiga Prefecture, Japan	57.9	—	—	—	8 programs
58	UB uBriGene Biosciences Shanghai, CN · Boston, MA	56.5	—	—	—	0 programs
59	CV CEVEC Pharmaceuticals Cologne, Germany	56.5	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Viral Vector CDMO

Vector platform match

First shortlist filter for any viral vector program is platform. AAV for in vivo systemic, lentiviral for ex vivo cell engineering, adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within.

Facility-level regulatory record on the platform

A CDMO's strong FDA record on AAV does not automatically de-risk their lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use, not the CDMO's aggregate score.

Analytics maturity per vector

Full/empty capsid separation for AAV, RCL testing for lentivirus, particle-to-infectivity ratio for adenovirus — each platform has non-negotiable release-testing requirements. A CDMO's qualified, validated assay panel for the specific vector is the single most under-appreciated cost driver in viral vector programs.

Capacity match to phase and dose

AAV early clinical runs at 50-200L, commercial at 1,000-2,000L single batch; lentiviral commercial supply is a narrower field with per-patient-dose economics. Confirm the CDMO's capacity headroom at your target phase before shortlisting — capacity constraints appear late and derail commercial launches.

Which viral vector platform does my program need?

The three GMP platforms map to distinct program types. AAV is the dominant delivery platform for in vivo gene therapy — rare disease, ophthalmology, neurology, cardiac, and musculoskeletal indications. It's non-integrating, made at 200-2,000L batch scale in suspension or adherent culture, and every approved in vivo gene therapy uses AAV. Lentivirus is the workhorse for ex vivo cell engineering — CAR-T, TCR, and gene-modified HSC programs use lentivirus to stably integrate the therapeutic gene into patient-bound cells. Lentiviral manufacturing runs at BSL-2 with mandatory replication-competent lentivirus (RCL) testing. Adenovirus retains relevance for vaccines and select gene therapy programs where high transient expression is acceptable — its non-integrating nature and strong immunogenicity make it well-suited for prime-boost vaccine architectures. Most CDMOs specialize in one or two platforms — filter by platform on the AAV, lentiviral, or adenoviral pages for the platform-specific shortlist.

What analytics differ across viral vector platforms?

Vector analytics drive lot release and directly determine batch success rate — they're the most under-appreciated cost driver in viral vector programs. AAV lot release requires titer (typically genome copies + capsid titer), full/empty capsid ratio (analytical ultracentrifugation, cIEF, or CDMS), aggregation, endotoxin, and increasingly potency assays that correlate with clinical activity. Lentivirus lot release requires infectious titer (usually functional/transducing units), vector copy number, replication-competent lentivirus (RCL) testing (a regulatory absolute), and residual host cell DNA/protein. Adenovirus lot release requires viral particle count, infectious titer, particle-to-infectivity ratio, and residual host cell proteins. CDMOs with qualified, established, and independently-validated assay platforms for the specific vector — not just the general capability to "run analytics" — meaningfully de-risk comparability and tech transfer.

How does CDMO Signal aggregate viral vector CDMOs?

The viral vector ranking is a union of CDMOs tagged with any of the three GMP-relevant vector platforms in our directory (AAV, lentiviral, adenoviral). Each CDMO appears once regardless of how many platforms they cover — a multi-platform manufacturer like Lonza, Thermo Fisher, or Catalent shows here at their composite Signal Score, and the individual platform pages break out platform-specific ranking positions. Signal Score is computed identically across all modalities; the aggregation doesn't inflate scores, it widens the candidate set.

Which viral vector CDMOs have commercial-approved product experience?

Manufacturing for approved viral vector products is the strongest possible buyer signal — it proves a facility has passed both a full BLA/MAA CMC review and a pre-approval inspection at commercial scale. Approved AAV gene therapies include Zolgensma (Novartis/AveXis, Novartis-manufactured then contract-manufactured), Luxturna (Spark, Novartis-manufactured), Roctavian (BioMarin), Elevidys (Sarepta, multiple CDMO partners); approved lentiviral cell therapies include Kymriah (Novartis), Yescarta (Gilead/Kite), Breyanzi (BMS), and bluebird bio's ex vivo gene therapies. CDMOs with named involvement in these programs carry demonstrated commercial posture. The Signal Score reflects this indirectly through inspection density and clinical footprint, but for late-stage program selection sponsors should cross-reference the individual CDMO profile pages with FDA approval history for direct evidence.

Viral Vector CDMOs — Frequently Asked Questions

Who are the top Viral Vector CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Viral Vector CDMOs include Takeda, Thermo Fisher Scientific, AGC Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Viral Vector CDMOs have FDA inspection records?

CDMO Signal tracks 18 Viral Vector CDMOs with FDA inspection records and 196 EMA/MHRA GMP certificates across the group.

What should I look for in a viral vector CDMO?

Match the vector platform first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, vector-specific analytics maturity, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific technical detail worth reading before finalizing a shortlist.

How many viral vector CDMOs does CDMO Signal track?

65+ CDMOs are tracked across the three GMP viral vector platforms — the union of AAV, lentiviral, and adenoviral manufacturers, deduplicated. Each is scored independently on the standard four-pillar Signal Score composite.

How is viral vector manufacturing different from mAb or recombinant protein biologics?

Viral vector manufacturing shares the mammalian cell culture upstream backbone with biologics but diverges sharply on downstream. Viral vector downstream requires enveloped/non-enveloped virus purification (chromatography, tangential flow filtration, ultracentrifugation) rather than protein A affinity capture. Analytics differ fundamentally — infectious titer and capsid analytics for viral vectors vs product-related impurities for biologics. Regulatory paths also differ: viral vectors carry additional biosafety review (RCL for lentivirus, adventitious agents for all platforms) beyond standard biologics.

Compare side-by-side

See two CDMOs' scoring, inspection history, and clinical footprint next to each other.

Open comparison →

Run a sourcing search

Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.

Search for a CDMO →

Save this Viral Vector shortlist

Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.

Related modalities

AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs Gene Therapy CDMOs Cell & Gene Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy